The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis
ConclusionOur analyses suggest that vitamin D supplementation, with or without calcium, does not reduce breast cancer risk by 30% or more. Future trials with similar designs are unlikely to alter this finding.
Authors: Wongsaengsak S, Quirch M, Ball S, Sultan A, Jahan N, Elmassry M, Rehman S Abstract Docetaxel is an anti-microtubule agent and a highly effective treatment of locally advanced and metastatic breast cancer. There are several adverse effects associated with docetaxel, such as myelosuppression, peripheral neuropathy, fluid retention, and asthenia. One of the most well-known side-effects of this medication is mild to moderate myalgia. Here, we report a case of a 49-year-old female with stage 3 breast cancers who developed severe acute myositis following docetaxel use. The mechanism of docetaxel-induced myositis...
This study aims to evaluate the photodynamic efficacy of purpurin 18 (pu-18) on triple negative breast cancer both in vitro and in vivo. Two states of 4T1 cells, 2D culture and 3D spheroids, were used to evaluate the photodynamic action of pu-18 in vitro. The in vitro study results indicated that for the 4T1 2D cell culture, the photodynamic therapy (PDT) treatment showed significant photocytotoxicity at low pu-18 concentrations following light irradiation. Pu-18 was found to distribute on the lysosomes, mitochondria, Golgi apparatus, and endoplasmic reticulum. After irradiation, pu-18 can generate ROS to destroy the mitoc...
Publication date: Available online 3 July 2020Source: European Journal of RadiologyAuthor(s): Dorothy Ibifuro Makanjuola, Abdulmohsen Alkushi, Khalid Al Anazi
Publication date: August 2020Source: IJC Heart &Vasculature, Volume 29Author(s): Januar Wibawa Martha, Dery A. Soedarsono, Mohammad Iqbal, Astri Astuti, Erwan Martanto, Mohammad Rizki Akbar, I. Gede Sumantra
Publication date: September 2020Source: Biomedicine &Pharmacotherapy, Volume 129Author(s): Ting Yang, Ziyi Fu, Yin Zhang, Min Wang, Changfei Mao, Weihong Ge
Publication date: Available online 2 July 2020Source: Seminars in Cancer BiologyAuthor(s): Nicola Gaynor, John Crown, Denis M. Collins
SummaryIbrutinib is a first-in-class Bruton ’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites, however, can reach substantial c oncentrations in human subjects, especially when CYP3A4 is inhibited. Ibrutinib has unexplained nephrotoxicity and high metabolite concentrations are also found in kidneys of Cyp3a knockout mice. Here, a mechanism is proposed where the intermediate cysteine metabolite is bioactiva...